Cancel
Rajshree Kandadai
Business Development
@
Acrivon Therapeutics
wpg1phsh9@x80feg9.se1
Sign up to see email
Known information
- Has over 20 years of experience in business development and licensing, corporate strategy, and alliance management roles.
- Previously led licensing activities for oncology assets at Mass General Brigham (MGB) Innovation for the Brigham and Woman’s Hospital, the Mass General Hospital, and the MGH Vaccine and Immunotherapy Center.
- Was responsible for driving several high-value transactions at Mass General Brigham (MGB) Innovation.
- From 2010 to 2019, served as Senior Director of Corporate Development and Strategy at Aurigene Oncology.
- Established over 15 collaborations with big pharma and biotech companies across the U.S., Europe, and Japan during tenure at Aurigene Oncology.
- Delivered over $250 million in realized revenues while at Aurigene Oncology.
- Previously served as a healthcare equity research analyst at UBS ISC and HSBC.
- Led the healthcare equity research team at UBS ISC.
- Covered the U.S. healthcare sector as an equity analyst at HSBC.
- Holds a Master’s degree in hospital management.
- Holds a B.S. in microbiology.
About Acrivon Therapeutics
Acrivon Therapeutics develops precision oncology medicines using a proprietary proteomics-based platform, with its lead candidate ACR-368 in a Phase 2 trial for multiple tumor types.
Report inaccurate information
